Related coverage linked through entity extraction aliases.
Jul 17, 2026
Ensitrelvir cut symptomatic COVID-19 after household exposure from 9% to 3% in a trial; Japan approved it for post-exposure use. A redesigned hepatitis C drug, ML2006a4, shows activity against resistant variants.
Jun 26, 2026
Studies reveal age-related infectious disease patterns including higher symptomatic rhinovirus risk in adults over 60, polypharmacy complications in infectious disease patients, and significant underutilization of COVID-19 antivirals among older adults despite proven benefits.
Apr 23, 2026
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Mar 08, 2026
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
